647 related articles for article (PubMed ID: 15877590)
1. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
3. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Bolin K; Lindgren B; Willers S
Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
[TBL] [Abstract][Full Text] [Related]
4. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
Bolin K; Mörk AC; Willers S; Lindgren B
Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
Cromwell J; Bartosch WJ; Fiore MC; Hasselblad V; Baker T
JAMA; 1997 Dec; 278(21):1759-66. PubMed ID: 9388153
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Hoogendoorn M; Welsing P; Rutten-van Mölken MP
Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of a telephone- and face-to-face-delivered counseling intervention for smoking cessation in patients with coronary heart disease.
Berndt N; Bolman C; Lechner L; Max W; Mudde A; de Vries H; Evers S
Eur J Health Econ; 2016 Apr; 17(3):269-85. PubMed ID: 25796578
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
10. [Economic evaluation of pharmacotherapies for smoking cessation].
Antoñanzas F; Portillo F
Gac Sanit; 2003; 17(5):393-403. PubMed ID: 14599422
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
[TBL] [Abstract][Full Text] [Related]
12. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY; Lim SS; Wallace AL; Vos T
Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
Song F; Raftery J; Aveyard P; Hyde C; Barton P; Woolacott N
Med Decis Making; 2002; 22(5 Suppl):S26-37. PubMed ID: 12369228
[TBL] [Abstract][Full Text] [Related]
15. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
Vemer P; Rutten-van Mölken MP
Value Health; 2010; 13(2):230-41. PubMed ID: 19804435
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling.
Fiscella K; Franks P
JAMA; 1996 Apr; 275(16):1247-51. PubMed ID: 8601956
[TBL] [Abstract][Full Text] [Related]
17. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands.
Vemer P; Rutten-van Mölken MP; Kaper J; Hoogenveen RT; van Schayck CP; Feenstra TL
Addiction; 2010 Jun; 105(6):1088-97. PubMed ID: 20659063
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the first-line therapies for nicotine dependence.
Cornuz J; Pinget C; Gilbert A; Paccaud F
Eur J Clin Pharmacol; 2003 Jul; 59(3):201-6. PubMed ID: 12759795
[TBL] [Abstract][Full Text] [Related]
19. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
[TBL] [Abstract][Full Text] [Related]
20. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
